A clinic visit, hospital admission, or transition in care often begins with medication reconciliation. Developed to provide safer, more coordinated, and better-quality care, medication reconciliation ...

Postdischarge adverse drug event risk is amplified by frequent medication changes, formulary substitutions, and insurance coverage gaps, with wide variability in published incidence estimates and ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Proper medication reconciliation can help prevent adverse drug events by identifying exactly what medications a patient was taking before coming to the hospital and confirming appropriate medication ...

The Agency for Healthcare Research and Quality provides a free, downloadable medications at transitions and clinical handoffs toolkit for medication reconciliation. Medication reconciliation is a ...

The elderly and chronically ill patients are typically challenged with many drugs and complicated dosing regimens, often leading to medication errors. Medication errors are one of the most common ...

Jeannie Pezone, administrator at West Park Surgery Center in Pinellas Park, Fla., explains the process the surgery center uses to ensure medication reconciliation is achieved according to standards ...

Medication errors are an all-too-common problem in the U.S. In fact, they affect nearly 5 percent of the nation’s hospitalized patients, according to the Agency for Healthcare Research and Quality. In ...

Objective Geriatric patients often face issues related to polypharmacy and adverse drug events. Re-evaluating prescribed medications and considering deprescribing is critical. Medication discrepancies ...

Medication reconciliation is “the process of comparing a patient’s medication orders to all of the medications that the patient has been taking.” 1 Strong evidence supports the value of reconciliation ...

Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors From December 2022 to January 2025, one MRT ...

2019 JUN 26 (NewsRx) -- By a News Reporter-Staff News Editor at Economics Daily Report -- Research findings on Sustainability Research are discussed in a new report. According to news reporting ...